X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs877373-   
Low Rs424269-   
Sales per share (Unadj.) Rs223.4111.1-  
Earnings per share (Unadj.) Rs31.1-28.0-  
Cash flow per share (Unadj.) Rs40.3-23.2-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.587.2-  
Shares outstanding (eoy) m33.07168.78-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.9 100.6%   
Avg P/E ratio x20.9-11.5 -182.3%  
P/CF ratio (eoy) x16.1-13.9 -116.5%  
Price / Book Value ratio x3.03.7 80.4%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50454,239 39.6%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m1,1283,404 33.1%   
Avg. sales/employee Rs ThNM4,366.6-  
Avg. wages/employee Rs ThNM793.0-  
Avg. net profit/employee Rs ThNM-1,100.3-  
INCOME DATA
Net Sales Rs m7,38918,746 39.4%  
Other income Rs m167131 127.3%   
Total revenues Rs m7,55618,877 40.0%   
Gross profit Rs m1,793-3,249 -55.2%  
Depreciation Rs m304809 37.6%   
Interest Rs m366508 72.1%   
Profit before tax Rs m1,290-4,434 -29.1%   
Minority Interest Rs m46-12 -374.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309277 111.4%   
Profit after tax Rs m1,027-4,724 -21.8%  
Gross profit margin %24.3-17.3 -140.1%  
Effective tax rate %23.9-6.2 -383.0%   
Net profit margin %13.9-25.2 -55.2%  
BALANCE SHEET DATA
Current assets Rs m3,68113,730 26.8%   
Current liabilities Rs m3,1237,725 40.4%   
Net working cap to sales %7.632.0 23.6%  
Current ratio x1.21.8 66.3%  
Inventory Days Days89111 80.7%  
Debtors Days Days59124 47.3%  
Net fixed assets Rs m7,6858,003 96.0%   
Share capital Rs m33187 380.0%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,25914,714 49.3%   
Long term debt Rs m9555,171 18.5%   
Total assets Rs m11,95727,795 43.0%  
Interest coverage x4.5-7.7 -58.5%   
Debt to equity ratio x0.10.4 37.4%  
Sales to assets ratio x0.60.7 91.6%   
Return on assets %11.7-15.2 -76.8%  
Return on equity %14.2-32.1 -44.1%  
Return on capital %20.7-19.8 -104.6%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,4401,600 90.0%  
From Investments Rs m-1,089-491 221.7%  
From Financial Activity Rs m-3534,693 -7.5%  
Net Cashflow Rs m-15,801 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.15 Rs / ZAR

Compare NATCO PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: CADILA HEALTHCARE  WYETH LTD  STERLING BIOTECH  ALEMBIC LTD  ELDER PHARMA  



Today's Market

Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)

Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.

Related Views On News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jul 18, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS